Financials
Financial year 2025
Deraphar from Zelzate, company number BE0439109003, closed financial year 2025 with a result of € -88,165 after tax. For that financial year Deraphar recorded a gross margin of € 104,127 and equity of € 270,143. Compared with financial year 2024, the result moved from € 3,538 to € -88,165. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 24, 2026.
€ 270,143
▼ 25% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -88,165
▼ still € 3,538 profit in 2024
Profit after tax over the fiscal year.
€ 60,739
▲ 114% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 251,551.
People and assets in 2025
1.9
▼ 0.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 129,537
▲ 3% vs 2024
€ 68,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 368,515
▼ 7% vs 2024
€ 59,532 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 129,140
▲ 54% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 8,844
▼ 39% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 90,576 | € 202,979 | € 191,616 | € 104,127 | ▼ 46% |
| Profit after taxes | € -90,789 | € 13,744 | € 3,538 | € -88,165 | ▼ € 91,703 |
| Equity | € 341,026 | € 354,770 | € 358,308 | € 270,143 | ▼ 25% |
| Total debts | € 886,322 | € 757,306 | € 497,200 | € 508,783 | ▲ 2% |
| Cash | € 77,131 | € 28,691 | € 28,362 | € 60,739 | ▲ 114% |
| Retained profit | € 322,434 | € 336,178 | € 339,716 | € 251,551 | ▼ 26% |
| Bank debt | € 432,046 | € 351,372 | € 396,319 | € 368,515 | ▼ 7% |
| Balance sheet total | € 1,227,348 | € 1,112,076 | € 855,507 | € 778,926 | ▼ 9% |
| Employees (FTE) | 2.4 | 1.9 | 2.1 | 1.9 | ▼ 0.2 |
Key figures of Deraphar, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Deraphar?
What happened at Deraphar in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 88,165 (▼ € 91,703 vs 2024). Source: NBB ↗
- Decura Pharma became a director. NBB
- New establishment in Zelzate. KBO
- Start of the company according to the CBE. KBO
In short
From € 90,789 loss in 2022 to € 88,165 loss in 2025.
Paid € 785 in corporate taxes since 2022.
Best year ever: 2023, with € 13,744 profit.
On average € 54,800 of value added per employee in 2025.
Management
The stake of DECURA PHARMA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
DerapharBehind Deraphar is Decura Pharma. The shares are held by DECURA PHARMA (99.9%). It owns Zorgpunt itself.
Directors
According to the 2025 annual accounts
Director · represented by Ann Raes
Also active at: MEDISALE, LINDEPHAR, APOTHEEK RAES, FIDELMED, PHARMA FIDELMED, HEALTH AND BEAUTY SHOP, DYNA DISTRIBUTION
since 2015
Shareholders
99.9%
Participations
Establishments
Establishment units
Physical locations of this company
Grote Markt 44
9060 Zelzate
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0439.109.003
- VAT number
- BE 0439.109.003
- Registered office
- Grote Markt 44, 9060 Zelzate
- Names & denominations
- Deraphar
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 4 December 1989
- Peppol
- Active · Active since 28 Aug 2023
- Activities · NACE
Apothekers
Detailhandel in farmaceutische producten